ClearPoint Neuro (CLPT) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

ClearPoint Neuro (CLPT) overview

ClearPoint Neuro (CLPT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 37.0m and operating profit of USD -24.2m; the year-end share price was 13.68 USD and market capitalisation was USD 402m. ClearPoint Neuro is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ClearPoint Neuro's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 28.0mFY 2025
Share price13.68 USDFY 2025 year end
RevenueUSD 37.0mFY 2025
Operating profitUSD -24.2mFY 2025
Net earningsUSD -25.5mFY 2025
Market capitalisationUSD 402mFY 2025 year end

About ClearPoint Neuro

ClearPoint Neuro develops and commercializes medical devices for neurosurgical procedures and provides services supporting biologics and drug delivery programs. Its products include the ClearPoint system for image-guided brain procedures, stereotactic systems for operating rooms, a neuro laser therapy system, and the IRRAflow system for intracranial fluid management. Its consulting and preclinical services support pharmaceutical, biotechnology, academic, and contract research organization partners.

Generate the ClearPoint Neuro report

ClearPoint Neuro is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ClearPoint Neuro and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on ClearPoint Neuro

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.